Improving Infant Hydrocephalus Outcomes in Uganda

NCT ID: NCT03650101

Last Updated: 2023-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-05

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neonatal postinfectious hydrocephalus (PIH) is a major public health problem in East Africa.The standard treatment has long been placement of a ventriculoperitoneal shunt (VPS) but these devices require life-long maintenance and nearly all fail multiple times. Endoscopic Third Ventriculostomy (ETV) with Choroid Plexus Cauterization (ETV/CPC) is an alternate treatment to give patients a shunt-free life. In this study, the investigators aim to optimize the metrics of evaluation as quantitative prognostic indicators of treatment response and long term outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hydrocephalus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrocephalus group

Inclusion criteria:

1. Age less than six months
2. Symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior fontanel, ventriculomegaly
3. A parent or a guardian qualified by Ugandan law to give informed consent
4. Patients from Eastern, Central and Northern districts of Uganda, and in geographic proximity to CURE hospital will be eligible

Exclusion criteria:

1. Age greater than six months
2. No evidence of progressive hydrocephalus
3. Patients outside of the districts specified in the inclusion criteria

ETV/CPC

Intervention Type PROCEDURE

The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.

Control group

Inclusion criteria:

1. Born at GA ≥ 37 weeks
2. Age less than six months at the time of enrollment
3. No known medical conditions
4. With a parent or a guardian qualified by Ugandan law to give informed consent
5. Parents live in one of the villages in the Mbale or Budaka District, in geographic proximity to CCHU.

Exclusion criteria:

1. Born at GA \< 37 weeks
2. Age greater than six months
3. Evidence of one or more medical conditions
4. Living outside of the districts specified in the inclusion criteria.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ETV/CPC

The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants less than 180 days (six months) old
* Symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior fontanel, ventriculomegaly
* A parent or a guardian qualified by Ugandan law to give informed consent
* Patients from Eastern, Central and Northern districts of Uganda, and in geographic proximity to CURE hospital will be eligible

Exclusion Criteria

* Age greater than six months
* No evidence of progressive hydrocephalus
Minimum Eligible Age

1 Day

Maximum Eligible Age

180 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Hospital for Sick Children

OTHER

Sponsor Role collaborator

CURE Children's Hospital, Uganda

OTHER

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role collaborator

Boston Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pei-Yi Lin

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pei-Yi Lin, PhD

Role: PRINCIPAL_INVESTIGATOR

Boston Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Penn State University

University Park, Pennsylvania, United States

Site Status ACTIVE_NOT_RECRUITING

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status ACTIVE_NOT_RECRUITING

Cure Children's Hospital of Uganda

Mbale, , Uganda

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Uganda

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pei-Yi Lin, PhD

Role: CONTACT

6179191308

Matthew Foster

Role: CONTACT

6179192729

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Edith Mbabazi, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Vadset TA, Rajaram A, Hsiao CH, Kemigisha Katungi M, Magombe J, Seruwu M, Kaaya Nsubuga B, Vyas R, Tatz J, Playter K, Nalule E, Natukwatsa D, Wabukoma M, Neri Perez LE, Mulondo R, Queally JT, Fenster A, Kulkarni AV, Schiff SJ, Grant PE, Mbabazi Kabachelor E, Warf BC, Sutin JDB, Lin PY. Improving Infant Hydrocephalus Outcomes in Uganda: A Longitudinal Prospective Study Protocol for Predicting Developmental Outcomes and Identifying Patients at Risk for Early Treatment Failure after ETV/CPC. Metabolites. 2022 Jan 14;12(1):78. doi: 10.3390/metabo12010078.

Reference Type RESULT
PMID: 35050201 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P00029806

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.